Healthcare has emerged as the leading S&P 500 sector as capital rotates away from AI‑focused stocks. After a hotter‑than‑expected CPI print on Wednesday sent technology shares 3 % lower, the healthcare index (XLV) gained 2.4 % and repeated its strength on Thursday with a 1.8 % rise. Over the five trading days through October 15, XLV was up 5.4 %, positioning the sector third in year‑to‑date performance at +12.4 %—just a point behind the broader index (+12.9 %). Energy (+51 %) and technology (+32 %) remain the only sectors ahead of the benchmark this year.
The sector entered 2026 with its forward price‑to‑earnings ratio in the lowest quintile of its 15‑year range, suggesting favorable valuation fundamentals. Analysts are therefore turning their focus to chart‑based signals within the healthcare space.
Waters Corporation (WAT)
Waters designs and manufactures high‑performance liquid chromatography and mass‑spectrometry instruments, consumables, and related software for pharmaceutical, biotechnology, academic, food, and environmental laboratories. The company’s February acquisition of BD’s Biosciences & Diagnostic Solutions roughly doubled its revenue base. After an initial dip following the deal announcement in July 2025, WAT hit a low of $283 in mid‑March 2026, down 24.6 % year to date. The stock has since recovered, climbing 57 % from that trough to $444—only 2 % below its record high of $454.54 set on October 6.
Waters reported Q2 2026 earnings on August 4, delivering revenue of $1.65 billion and adjusted earnings per share of $3.05, both beating consensus. The legacy WAT business contributed $828 million (+9 % YoY) while the new BD unit added $817 million (+4 %). Management raised its full‑year organic constant‑currency growth guidance to 7 %–9 % and adjusted EPS to $14.45‑$14.65 (+10‑12 %). For Q3, WAT forecasts revenue of $1.75‑$1.762 billion and EPS of $3.95‑$4.05.
Technically, WAT broke out of a spring base in late May and surged on the earnings report, posting a $40 single‑session gain on roughly double average volume. After peaking near $455 on October 6, the stock has been consolidating between $422 and $450. Key support levels are observed at $390 (a repeated September low) and the rising 50‑day moving average at $421. A close below $420 would signal a breakdown of the current range, while a weekly close under $390 would indicate the uptrend has faltered. Traders are advised to set a stop at $420 based on closing prices; investors may anchor to the $390 level.
Thermo Fisher Scientific, Inc. (TMO)
Thermo Fisher is the largest provider of life‑science tools, generating approximately $46 billion in trailing revenue. Its product portfolio includes analytical instruments, lab consumables, diagnostics systems, and bioproduction equipment, complemented by pharma services and clinical‑research outsourcing. Pharmaceutical and biotechnology customers account for roughly 60 % of sales.
TMO has enjoyed robust momentum. The stock is up 19 % since being highlighted on November 24, 2025, and closed Thursday at a record $696.49, giving the company a market capitalization of $257.5 billion. The share price is 60 % above its 52‑week low of $435.27, reflecting a 20.5 % year‑to‑date gain and a 31 % increase since mid‑July, just ahead of the Q2 earnings release.
Q2 results reported in July showed revenue of $11.99 billion (+10 % YoY, +5 % organic) and adjusted EPS of $6.03 (+13 %). Adjusted operating margin expanded 0.9 percentage points to 22.8 %. Management raised full‑year revenue guidance to $47.4‑$48.1 billion and adjusted EPS to $24.93‑$25.33 (+9‑11 %). Free‑cash‑flow guidance stands at $6.9‑$7.4 billion, and a $4 billion share‑repurchase program is planned. Recent acquisitions of Clario and Solventum filtration businesses and the divestiture of its microbiology unit for $1.075 billion in August have strengthened the platform.
Technical analysis shows TMO gapped upward on July 23 after the Q2 report, opening near $570 versus a prior close in the $520s. The gap has remained unfilled for three months, with the stock never falling below $555 since. After reaching a high near $693 on October 6, the share pulled back before reclaiming new highs on Thursday. The current price sits at $690, with the 50‑day moving average at $637 and the 200‑day at $547. The critical resistance is Thursday’s high near $703, while support is observed at $650 (the September‑October range bottom) and $600 (the early September low). A weekly close below $600 would suggest the uptrend initiated with the July gap has lost traction. Traders are advised to monitor a breach of $650 for a potential reversal; investors may view $600 as a longer‑term anchor.
The healthcare sector’s strong performance, combined with compelling technical setups in Waters and Thermo Fisher, underscores the area’s attractiveness as AI‑related momentum wanes. Investors should weigh the sector’s robust fundamentals and recent earnings trends against the noted technical levels before making positioning decisions.
